BIIB vs TRDA
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. TRDA: Entrada Therapeutics is developing a new class of intracellular genetic medicines using its proprietary endosomal escape vehicle technology to treat serious neuromuscular and retinal diseases.
Side-by-side fundamentals
| Metric | BIIB | TRDA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $218.43 | $5.53 | |
| Market cap | $32.2B | $215M | |
| P/E as of 2026-10-08 | 38.68 | n/a | |
| Net margin FY2025, SEC XBRL | +13.1% | -565.5% | BIIB higher |
| Operating margin | +25.9% | -621.1% | BIIB higher |
| ROE FY2025, SEC XBRL | +7.1% | -47.0% | BIIB higher |
| ROA FY2025, SEC XBRL | +4.4% | -38.1% | BIIB higher |
| Debt / equity as of 2026-09-03 | 0.43 | 0.00 | TRDA lower |
| Revenue growth (YoY) as of 2026-09-03 | +0.3% | -94.1% | BIIB higher |
| Revenue CAGR (3y) SEC XBRL | -0.9% | -55.6% | BIIB higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.51 | 1.18 | |
| 1-year return as of 2026-10-08 close | +44.7% | -10.2% | BIIB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.